Fernanda Costa Svedman

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella et al. · Journal of Clinical Oncology · 2022 · 127 citations

Medicine, Oncology, Pharmacotherapy +17

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

Alireza Azimi, Rainer Tuominen, Fernanda Costa Svedman et al. · Cell Death and Disease · 2017 · 49 citations · Full text

Medicine, Molecular Biology, Oncology +17

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma

Fernanda Costa Svedman, Warangkana Lohcharoenkal, Matteo Bottai et al. · PLoS ONE · 2018 · 43 citations · Full text

Medicine, Molecular Medicine, Oncology +16

Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy

Max Karlsson, Fernanda Costa Svedman, Abdellah Tebani et al. · Cancer Research · 2021 · 37 citations · Full text

Medicine, Dermatology, Oncology +17

Prostasin, A Potential Tumor Marker in Ovarian Cancer- A Pilot Study

Fernanda Costa Svedman, Eraldo L. Batista, Alice Zelmanowicz et al. · Clinics · 2009 · 32 citations · Full text

Medicine, Molecular Biology, Oncology +12